, also marketed under the name Redux
, is a serotoninergic anorectic
drug. It was for some years in the mid-1990s approved by the United States Food and Drug Administration
for the purposes of weight loss
. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was withdrawn. After it was removed in the US, dexfenfluramine was also pulled out in other global markets. It was later superseded by sibutramine
, which is a safer alternative to both dexfenfluramine and fenfluramine
The drug was manufactured by Interneuron Pharmaceuticals and marketed by Wyeth-Ayerst Laboratories. It is the enantiomer of levofenfluramine.